Open AccessA Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy
Author(s) -
Hui Yang,
Shaoxing Sun,
Zijie Mei,
Qingming Xiang,
Chunxu Yang,
Min Chen,
Conghua Xie,
Yunfeng Zhou,
Hui Qiu
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s335870
Subject(s) - apatinib , medicine , oncology , retrospective cohort study , cervical cancer , bevacizumab , cancer , progression free survival , gastroenterology , chemotherapy
Anlotinib is an oral anti-angiogenesis inhibitor targeting vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors, fibroblast growth factor receptors, etc., and its clinical value in cervical cancer is rarely reported. We designed a retrospective study to evaluate the efficacy and safety of anlotinib in patients with persistent, metastatic, or recurrent cervical cancer who have failed first-line therapy, and compare the efficacy of anlotinib with that of apatinib which targets only VEGFR2 and has shown efficacy in recent studies.